Potassium-Removing Drug Effective in Dialysis Patients Potassium-Removing Drug Effective in Dialysis Patients
Sodium zirconium cyclosilicate effectively treats hyperkalemia in patients receiving hemodialysis for end-stage kidney disease, and no new safety concerns were observed in the phase 3 DIALIZE study.Medscape Medical News
CONCLUSIONS: Tx-ESRD patients have worse quality metrics related to anemia, phosphorus, albumin, and vascular access compared to Nat-ESRD patients. Nephrology care for patients with Tx-ESRD should be improved to address these quality metrics gaps. PMID: 31311008 [PubMed - as supplied by publisher]
ConclusionThis study suggests that kidney transplantation is a better option over hemodialysis and peritoneal dialysis. We conclude that serious efforts ought to be made to foster potential brain-dead donors and altruistic kidney donation and promote peritoneal dialysis as a superior alternative to hemodialysis for eligible patients.
This study developed a prediction tool for transition from PD to HD.Study DesignRetrospective cohort study.Setting &ParticipantsAdults initiating PD between January 2008 and December 2011, followed up through June 2015, for whom data were available in the US Renal Data System (USRDS).PredictorsClinical characteristics at PD initiation and peritonitis claims.OutcomesTransfer to HD, with the competing outcomes of death and kidney transplantation.Analytical ApproachOutcomes were ascertained from USRDS treatment history files. Subdistribution hazards (competing-risk) models were fit using clinical characteristics at PD ini...
ConclusionClinicians prescribing ICIs should be aware that SOT recipients are at risk of transplant rejection as a result of T cell activation. Dd-cfDNA is a sensitive biomarker and should be further studied for early detection of transplant rejection. Immunological analysis of the kidney explant showed marked graft infiltration with alloreactive PD-1+ cytotoxic T cells that were saturated with nivolumab.
A package of initiatives aims to prolong lives, offer alternatives to center-based hemodialysis and save money.
Shares of dialysis providers DaVita Healthcare (NYSE:DVA) and Fresenius (NYSE:FMS) took a hit today after a report surfaced that the Trump administration is readying an overhaul of the kidney treatment market. The president plans to issue an executive order tomorrow that would seek to incentivize kidney transplants and home hemodialysis in a bid to lower the federal government’s annual $100 billion kidney care tab, Politico reported, citing “two individuals with knowledge of the announcement.” The strategy involves new payment models from the U.S. Health &Human Services Dept. designed to move pat...
CONCLUSIONS: Reduction of dialysate temperature may prevent IDH, but the conclusion is uncertain. Larger studies that measure important outcomes for HD patients are required to assess the effect of reduction of dialysate temperature. Six ongoing studies may provide much-needed high quality evidence in the future. PMID: 31273758 [PubMed - as supplied by publisher]
CONCLUSIONS: Patient survival may be lower in kidney transplant recipients with amyloidosis compared with patients with end-stage renal disease due to other causes. However, graft failure and acute rejection rates seem to be similar. PMID: 31266438 [PubMed - as supplied by publisher]
CONCLUSION: Brachial artery aneurysms are a rare complication in kidney transplant recipients after ligation of arteriovenous access for haemodialysis. Here, we report a case in which this condition is associated with an even rarer plasmablastic lymphoma. A common aetiology, due to immunosuppressive therapy, is postulated for the two coexisting diseases. PMID: 31244374 [PubMed - as supplied by publisher]
ConclusionsWe could not find a relationship between serum fetuin-A levels and valvular calcification in kidney recipients. In this population, further studies are needed to assess the role of serum fetuin-A in valvular calcification.